Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

- Significant clinical progress noted in small cell lung, prostate and

colorectal cancer trials -

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today provided an update of its picoplatin development program in small cell lung cancer (SCLC), colorectal cancer (CRC) and hormone refractory prostate cancer (HRPC), and its oral formulation in solid tumors. Presenting at the Lazard Capital Markets Healthcare Conference in New York, Jerry McMahon, Ph.D., chairman and CEO of Poniard, noted that the Company has made significant progress in 2007 in its clinical development program for picoplatin, its lead product candidate.

"2007 has been an important year for Poniard, as we have continued to advance our development of picoplatin, a new generation chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations," said Dr. McMahon. "We continue to drive our clinical programs toward completion and have achieved significant milestones this year. In addition, we remain on track to file our NDA for picoplatin in 2009."

Poniard is providing an update on the progress on all four of its picoplatin clinical trials, as follows:

Phase 3 SPEAR Trial:

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

To date
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Cataracts are the leading cause of ... of Ophthalmology, aging is the leading cause of eye ... natural lens. 22 million Americans age 40 and older ... to age, that number will increase over 30 million. ... iPads, smart-phones and computers, the demographic of ages 40 ...
(Date:6/18/2013)... , June 18, 2013  Decision Resources, ... firms for pharmaceutical and healthcare issues, announces that ... of the Middle East ... Tracker analyzes the challenges and opportunities to gaining ... international regions comprising 24 countries. The countries covered ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 ... Gilead Sciences, Inc. (NASDAQ: GILD ), Health Management ... (NASDAQ: IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ... readers may access these reports free of charge - including ... the links below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:New Vision Hope For Millions Undergoing Cataract Surgery 2New Vision Hope For Millions Undergoing Cataract Surgery 3Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... a compression garment distributor, has announced that the redesigned ... An alternative to compression stockings , the garments ... knee and thigh, and resemble an athletic brace. ... been out for several years, but they recently made ...
... Calif., Dec. 14, 2011  Amgen (NASDAQ: AMGN ) ... tender offer, which expired at 12:00 midnight, New York City ... has accepted for purchase 83,333,333 shares of its common stock ... cost of approximately $5 billion, excluding fees and expenses relating ...
Cached Medicine Technology:BrightLife Direct Introduces Redesigned Solaris ReadyWrap Quick-Fit 2Amgen Announces Final Results of Its Tender Offer 2Amgen Announces Final Results of Its Tender Offer 3
(Date:6/18/2013)... June 18, 2013 David Connett, DO, ... Family Medicine for the College of Osteopathic Medicine of ... has been elected president of the Osteopathic Medical ... Brown Jr. appointed Connett, a 1984 alumnus of COMP, ... recently elected Connett to the position during a conference ...
(Date:6/18/2013)... N.Y., June 18, 2013 -- Lauren Sciences, a ... V-Smart nanovesicle platform technology, announced today that it ... Drug Delivery with its V-Smart Platform, and selected ... by MCD Group. , The report, ... Start-ups and Emerging Companies ," features companies MCD ...
(Date:6/18/2013)... enrolled their first patients in the ROADSTER Study, a ... to help clear blockages in carotid arteries and prevent ... in the United States are diagnosed with blockages, or ... blockages can slow or even stop blood flow to ... as a "brain attack." , Current treatment options ...
(Date:6/18/2013)... scrambling to gather data for the FDA to support ... injury in the United States. The University of Rochester ... the Journal of Neurotrauma that it might ... of one., Jeffrey J. Bazarian, M.D., M.P.H., an associate ... first to show that measuring a combination of two ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2
... and research on guayule and lesquerella, two native Big Bend ... a Texas AgriLife Research scientist said. , Dr. Mike Foster, ... Center at Lubbock, said he is looking at the possibility ... Trans-Pecos and High Plains. Foster, who is located at the ...
... coverage isn,t reinstated, NEW YORK, Feb. 1 ... to cover Propofol under all circumstances,is getting louder. And ... call to file a consumer fraud lawsuit,against Aetna is ... York State issue has now become a national,campaign., ...
... on MySpace and Facebook, study finds , , FRIDAY, Feb. ... such as MySpace and Facebook have been singled out ... of the unwanted solicitation actually happens in chat rooms ... Even there, only 15 percent of children experience unwanted ...
... Patients with rheumatoid arthritis (RA), the most common ... other individuals to experience depression. Although depression in ... have examined whether rheumatologists and RA patients discuss ... in the February issue of Arthritis Care & ...
... American Heart Association,s ,Go Red for Women, Movement in ... ... As a leader in,cardiovascular treatment and the exclusive Bay Area "hometown" partner ... with the American Heart Association (AHA) to raise awareness,about heart disease, the ...
... (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth ... which demonstrated that ENBREL reduced C-reactive protein (CRP), a ... plaque psoriasis following 12 weeks of treatment. Median ... the ENBREL treated group compared to the placebo treated ...
Cached Medicine News:Health News:Growing markets bring potential for rubber and oilseed crops 2Health News:Growing markets bring potential for rubber and oilseed crops 3Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 2Health News:National Health Care Alliance Gains New Members Against Aetna's New Anesthesia Policy 3Health News:Social Networking Sites Safer Than IM or Chat Rooms 2Health News:Social Networking Sites Safer Than IM or Chat Rooms 3Health News:Depression not discussed during rheumatoid arthritis doctor visits 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 2Health News:Abbott 'Goes Red' to Educate Bay Area Women About Heart Disease 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... Durable ergonomic chairs with concave seats ... Select options like seats, backrests, armrests, and ... Series for top performance in a variety ... room, static control, health care and office. ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
Medicine Products: